Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Recruiting

Phase 1

Donor NK Cells, Cyclophosphamide, EtoposideDonor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT03420963

Conditions

Recurrent Cutaneous Melanoma

Recurrent Lip and Oral Cavity Carcinoma

Recurrent Malignant Endocrine Neoplasm

Recurrent Malignant Female Reproductive System Neoplasm

Recurrent Malignant Male Reproductive System Neoplasm

Eligibility Criteria

Sex: All

Age: 12 - 40

Healthy Volunteers: Not accepted

Interventions

Cord Blood-derived Expanded Allogeneic Natural Killer Cells

Cyclophosphamide

Etoposide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-18. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-08-13.